Literature DB >> 10519447

Population pharmacokinetics of gentamicin in preterm neonates: evaluation of a once-daily dosage regimen.

M L Vervelde1, C M Rademaker, T G Krediet, A Fleer, P van Asten, A van Dijk.   

Abstract

Population pharmacokinetic parameters of gentamicin in preterm neonates on a once-daily dosage regimen of 3.0 mg/kg given intravenously every 24 hours were established prospectively. In 34 preterm neonates with a mean gestational age of 32 +/- 4 (SD), 182 serum gentamicin levels (91 peak/trough pairs) were determined. Individual adjustments of dose or dosage interval were calculated by computer-aided Bayesian forecasting. The parameters Vd, ke, and CL for each patient were obtained by the nonparametric estimation of maximization method. The predictive power of the model was calculated and the pharmacokinetic estimates were statistically analyzed with SPSS/PC. Cluster analysis showed a division into 2 subpopulations (designated 1 and 2) on the basis of postnatal age. The mean +/- SD postnatal age of subpopulation 1 (n = 29) was 6 +/- 2 days (range 1-7) and of subpopulation 2 (n = 5) 15 +/- 4 days (range 12-24). The mean +/- SD gentamicin relative clearances of subpopulation 1 and subpopulation 2 were 0.0515 +/- 0.0128 and 0.1026 +/- 0.0102 L kg(-1) hr(-1), respectively (p < 0.05). The mean +/- SD values for Vd (Lkg(-1)) in both populations 1 and 2 were 0.6916 +/- 0.1670 and 0.7509 +/- 0.1961, respectively (not significantly different). For ke these data were 0.0744 +/- 0.0200 and 0.1366 +/- 0.0522 (p < 0.05). Statistics showed that the data for Vd and ke of subpopulation 1 were normally distributed (Vd and ke skewness 1.61 and 1.46; kurtosis 3.09 and 3.10 respectively). The model yielded a bias of -0.11 mg/L and a precision of 0.36 mg/L. It is recommended that gentamicin be started in a dosage of 3.5 mg/kg intravenously once-daily under close monitoring.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10519447     DOI: 10.1097/00007691-199910000-00004

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  16 in total

Review 1.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Acute effects of gentamicin on glomerular and tubular functions in preterm neonates.

Authors:  Sevinç Tugay; Zelal Bircan; Ciğdem Cağlayan; Ayşe Engin Arisoy; Ayşe Sevim Gökalp
Journal:  Pediatr Nephrol       Date:  2006-08-01       Impact factor: 3.714

3.  A mechanistic approach for the scaling of clearance in children.

Authors:  Andrea N Edginton; Walter Schmitt; Barbara Voith; Stefan Willmann
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Accuracy of empiric gentamicin dosing guidelines in neonates.

Authors:  Anna E Hitron; Yao Sun; Sarah B Scarpace
Journal:  J Pediatr Pharmacol Ther       Date:  2010-10

5.  Gentamicin pharmacokinetics in preterm infants with a patent and a closed ductus arteriosus.

Authors:  D J Touw; J H Proost; R Stevens; H N Lafeber; M M van Weissenbruch
Journal:  Pharm World Sci       Date:  2001-10

6.  Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children.

Authors:  J M Tréluyer; Y Merlé; S Tonnelier; E Rey; G Pons
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

Review 7.  Therapeutic drug monitoring of aminoglycosides in neonates.

Authors:  Daniël J Touw; Elsbeth M Westerman; Arwen J Sprij
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics of aminoglycosides in the neonate: a review.

Authors:  Gian Maria Pacifici
Journal:  Eur J Clin Pharmacol       Date:  2008-12-23       Impact factor: 2.953

Review 9.  Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.

Authors:  Jessica K Roberts; Chris Stockmann; Jonathan E Constance; Justin Stiers; Michael G Spigarelli; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

Review 10.  Extended-interval dosing of gentamicin for treatment of neonatal sepsis in developed and developing countries.

Authors:  Gary L Darmstadt; Mary Miller-Bell; Maneesh Batra; Paul Law; Kiely Law
Journal:  J Health Popul Nutr       Date:  2008-06       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.